Saba Capital Management, L.P. Acquires 2,022 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock

Abrdn Life Sciences Investors (NYSE:HQL) major shareholder Saba Capital Management, L.P. bought 2,022 shares of Abrdn Life Sciences Investors stock in a transaction dated Monday, April 22nd. The stock was purchased at an average price of $12.88 per share, with a total value of $26,043.36. Following the completion of the purchase, the insider now owns 2,738,992 shares in the company, valued at $35,278,216.96. The purchase was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Thursday, April 18th, Saba Capital Management, L.P. bought 81,738 shares of Abrdn Life Sciences Investors stock. The stock was purchased at an average price of $12.80 per share, with a total value of $1,046,246.40.

Abrdn Life Sciences Investors Trading Down 0.2 %

HQL stock opened at $13.13 on Thursday. Abrdn Life Sciences Investors has a 52-week low of $11.34 and a 52-week high of $14.37. The business has a 50-day simple moving average of $13.53 and a two-hundred day simple moving average of $13.10.

Abrdn Life Sciences Investors Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Thursday, February 22nd were paid a dividend of $0.39 per share. The ex-dividend date was Wednesday, February 21st. This represents a $1.56 dividend on an annualized basis and a yield of 11.88%. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.30.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

A number of hedge funds have recently added to or reduced their stakes in HQL. Future Financial Wealth Managment LLC acquired a new position in Abrdn Life Sciences Investors during the 1st quarter valued at about $27,000. Matisse Capital acquired a new position in Abrdn Life Sciences Investors during the 4th quarter valued at about $135,000. Blue Bell Private Wealth Management LLC boosted its stake in Abrdn Life Sciences Investors by 60.4% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 10,125 shares of the company’s stock valued at $136,000 after purchasing an additional 3,811 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of Abrdn Life Sciences Investors by 3,424.5% during the 4th quarter. International Assets Investment Management LLC now owns 11,067 shares of the company’s stock worth $149,000 after buying an additional 10,753 shares in the last quarter. Finally, CTC Alternative Strategies Ltd. bought a new position in shares of Abrdn Life Sciences Investors during the 4th quarter worth approximately $150,000. Institutional investors and hedge funds own 32.21% of the company’s stock.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.